Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES StudyCristina Masini, Carmine Pinto, Ilaria Zampiva et al.|European Urology|2021Cited by 110
First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES studyCristina Masini, Carmine Pinto, Patrizia Ciammella et al.|Annals of Oncology|2019Cited by 0
PO-1217: Safety of Nivolumab and stereotactic RT in metastatic renal carcinoma: early results of NIVES studyPatrizia Ciammella, Cinzia Iotti, Giorgia Timon et al.|Radiotherapy and Oncology|2020Cited by 0